Comparative/JJ
Modeling/JJ
and/CC
Molecular/JJ
Dynamics/NNS
Simulation/NN
of/IN
Substrate/JJ
Binding/NN
in/IN
Human/JJ
Fatty/NN
Acid/NN
Synthase/NN
:/:
Enoyl/NN
Reductase/NN
and/CC
β-Ketoacyl/NN
Reductase/NN
Catalytic/JJ
Domains/NNS
./.
====================
Fatty/JJ
acid/NN
synthase/NN
(/(
FASN/NN
,/,
EC/NN
2.3.1.85/CD
)/)
,/,
is/VBZ
a/DT
multi-enzyme/JJ
dimer/NN
complex/NN
that/WDT
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
lipogenesis/NN
./.
====================
This/DT
lipogenic/JJ
enzyme/NN
has/VBZ
gained/VBN
importance/NN
beyond/IN
its/PRP$
physiological/JJ
role/NN
due/IN
to/TO
its/PRP$
implications/NNS
in/IN
several/JJ
clinical/JJ
conditions-cancers/NNS
,/,
obesity/NN
,/,
and/CC
diabetes/VBZ
./.
====================
This/DT
has/VBZ
made/VBN
FASN/NN
an/DT
attractive/JJ
pharmacological/JJ
target/NN
./.
====================
Here/RB
,/,
we/PRP
have/VBP
attempted/VBN
to/TO
predict/VB
the/DT
theoretical/JJ
models/NNS
for/IN
the/DT
human/JJ
enoyl/NN
reductase/NN
(/(
ER/NN
)/)
and/CC
β-ketoacyl/JJ
reductase/NN
(/(
KR/NN
)/)
domains/NNS
based/VBN
on/IN
the/DT
porcine/NN
FASN/NN
crystal/JJ
structure/NN
,/,
which/WDT
was/VBD
the/DT
structurally/RB
closest/JJS
template/NN
available/JJ
at/IN
the/DT
time/NN
of/IN
this/DT
study/NN
./.
====================
Comparative/JJ
modeling/VBG
methods/NNS
were/VBD
used/VBN
for/IN
studying/VBG
the/DT
structure-function/JJ
relationships/NNS
./.
====================
Different/JJ
validation/NN
studies/NNS
revealed/VBD
the/DT
predicted/VBN
structures/NNS
to/TO
be/VB
highly/RB
plausible/JJ
./.
====================
The/DT
respective/JJ
substrates/NNS
of/IN
ER/NN
and/CC
KR/NN
domains-namely/RB
,/,
trans-butenoyl/NN
and/CC
β-ketobutyryl-were/VBD
computationally/RB
docked/VBD
into/IN
active/JJ
sites/NNS
using/VBG
Glide/NN
in/IN
order/NN
to/TO
understand/VB
the/DT
probable/JJ
binding/NN
mode/NN
./.
====================
The/DT
molecular/JJ
dynamics/NNS
simulations/NNS
of/IN
the/DT
apo/NN
and/CC
holo/JJ
states/NNS
of/IN
ER/NN
and/CC
KR/NN
showed/VBD
stable/JJ
backbone/NN
root/NN
mean/NN
square/VBP
deviation/NN
trajectories/VBZ
with/IN
minimal/JJ
deviation/NN
./.
====================
Ramachandran/NN
plot/NN
analysis/NN
showed/VBD
96.0/CD
%/NN
of/IN
residues/NNS
in/IN
the/DT
most/JJS
favorable/JJ
region/NN
for/IN
ER/NN
and/CC
90.3/CD
%/NN
for/IN
the/DT
KR/NN
domain/NN
,/,
respectively/RB
./.
====================
Thus/RB
,/,
the/DT
predicted/VBN
models/NNS
yielded/VBD
significant/JJ
insights/NNS
into/IN
the/DT
substrate/NN
binding/VBG
modes/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
catalytic/JJ
domains/NNS
and/CC
will/MD
aid/VB
in/IN
identifying/VBG
novel/JJ
chemical/JJ
inhibitors/NNS
of/IN
human/JJ
FASN/NN
that/DT
target/NN
these/DT
domains/NNS
./.
====================
Fatty/JJ
acid/NN
synthase/NN
(/(
FASN/NN
,/,
E.C/NN
./.
====================
2.3.1.85/CD
)/)
is/VBZ
a/DT
multi-enzyme/JJ
complex/NN
that/WDT
synthesizes/VBZ
endogenous/JJ
fatty/JJ
acids/NNS
./.
====================
Seven/CD
cycles/NNS
of/IN
FASN-catalyzed/JJ
reactions/NNS
result/NN
in/IN
the/DT
conversion/NN
of/IN
acetyl-CoA/NN
and/CC
malonyl-CoA/NN
into/IN
16-carbon/JJ
palmitate/JJ
[/(
1/CD
,/,
2/CD
]/)
by/IN
the/DT
successive/JJ
addition/NN
of/IN
2-carbon/JJ
units/NNS
per/IN
synthesis/NN
cycle/NN
./.
====================
Acyl/NN
carrier/NN
protein/NN
(/(
ACP/NN
)/)
holds/VBZ
the/DT
growing/VBG
chain/NN
covalently/RB
and/CC
transports/VBZ
it/PRP
sequentially/RB
to/TO
the/DT
active/JJ
sites/NNS
of/IN
β-ketoacyl/JJ
synthase/NN
(/(
KS/NNS
)/)
,/,
acetyl/NN
transacylase/NN
,/,
malonyl/JJ
transacylase/JJ
,/,
β-hydroxy/RB
acyl/JJ
dehydratase/NN
,/,
enoyl/NN
reductase/NN
(/(
ER/NN
)/)
,/,
β-ketoacyl/JJ
reductase/NN
(/(
KR/NN
)/)
,/,
and/CC
finally/RB
thioesterase/DT
(/(
TE/NNP
)/)
,/,
from/IN
which/WDT
palmitate/VBP
is/VBZ
cleaved/VBN
by/IN
catalytic/JJ
actions/NNS
./.
====================
Two/CD
major/JJ
forms/NNS
of/IN
FASN/NN
are/VBP
known/VBN
:/:
FASN/NN
type/NN
I/CD
(/(
FASNI/NN
)/)
and/CC
type/NN
II/CD
./.
====================
FASNI/NN
is/VBZ
a/DT
multimeric/JJ
multi-enzyme/JJ
complex/NN
involved/VBN
in/IN
the/DT
synthesis/NN
of/IN
palmitate/JJ
in/IN
an/DT
integrative/JJ
manner/NN
on/IN
a/DT
single/JJ
polypeptide/NN
chain/NN
(/(
α/LS
)/)
or/CC
on/IN
two/CD
different/JJ
polypeptides/NNS
(/(
α/LS
and/CC
β/FW
)/)
./.
====================
FASNI/NN
is/VBZ
further/RBR
subdivided/VBD
into/IN
two/CD
subtypes/NNS
./.
====================
Animal/JJ
FASN/NN
,/,
which/WDT
is/VBZ
a/DT
homodimeric/JJ
protein/NN
(/(
α2/LS
)/)
,/,
is/VBZ
arranged/VBN
head/RB
to/TO
tail/NN
[/(
3/CD
]/)
,/,
and/CC
the/DT
microbial/JJ
subgroup/NN
FASN/NN
,/,
which/WDT
is/VBZ
an/DT
oligomer/JJ
of/IN
higher/JJR
order/NN
,/,
consists/VBZ
of/IN
certain/JJ
bacterial/JJ
FASN/NN
type/NN
I/CD
α6/CD
hexamers/NNS
and/CC
of/IN
fungal/JJ
α6β6/CD
dodecomers/NNS
[/(
4/CD
]/)
./.
====================
Type/NN
II/CD
FASN/NN
consists/VBZ
of/IN
independent/JJ
proteins/NNS
that/WDT
catalyze/VBP
individual/JJ
reactions/NNS
and/CC
is/VBZ
present/JJ
in/IN
bacteria/NNS
,/,
plants/NNS
,/,
and/CC
eukaryotic/JJ
mitochondria/NN
[/(
5/CD
]/)
./.
====================
Besides/RB
the/DT
important/JJ
biochemical/JJ
role/NN
that/WDT
FASN/NN
plays/VBZ
in/IN
lipid/NN
biogenesis/NN
,/,
this/DT
complex/NN
enzyme/NN
has/VBZ
been/VBN
implicated/VBN
in/IN
several/JJ
pathological/JJ
conditions/NNS
./.
====================
In/IN
comparison/NN
with/IN
normal/JJ
cells/NNS
,/,
the/DT
overexpression/NN
of/IN
FASN/NN
has/VBZ
been/VBN
reported/VBN
in/IN
several/JJ
types/NNS
of/IN
cancers/NNS
,/,
including/VBG
prostrate/JJ
,/,
breast/NN
,/,
ovarian/JJ
,/,
and/CC
colon/NN
cancers/NNS
[/(
6/CD
,/,
7/CD
,/,
8/CD
]/)
,/,
which/WDT
strongly/RB
suggests/VBZ
the/DT
involvement/NN
of/IN
FASN/NN
in/IN
cancer/NN
progression/NN
./.
====================
Similarly/RB
,/,
FASN/NN
overexpression/NN
in/IN
ocular/JJ
cancer/NN
and/CC
retinoblastoma/NN
and/CC
its/PRP$
potential/JJ
as/IN
an/DT
anti-cancer/JJ
target/NN
using/VBG
enzyme/NN
inhibitors/NNS
have/VBP
been/VBN
reported/VBN
from/IN
our/PRP$
lab/NN
[/(
9/CD
]/)
./.
====================
FASN/NN
is/VBZ
also/RB
indicated/VBD
to/TO
have/VB
a/DT
potential/JJ
role/NN
in/IN
the/DT
clinical/JJ
management/NN
of/IN
microbial/JJ
infections/NNS
,/,
obesity/NN
,/,
and/CC
diabetes/VBZ
./.
====================
This/DT
enzyme/NN
is/VBZ
a/DT
potential/JJ
target/NN
to/TO
control/JJ
bacterial/JJ
infections/NNS
by/IN
using/VBG
agents/NNS
,/,
such/JJ
as/IN
cerulenin/JJ
and/CC
triclosan/NN
[/(
10/CD
]/)
,/,
and/CC
an/DT
anti-tumor/JJ
target/NN
against/IN
different/JJ
cancers/NNS
[/(
11/CD
]/)
and/CC
is/VBZ
also/RB
targeted/VBN
for/IN
the/DT
treatment/NN
of/IN
obesity/NN
[/(
12/CD
,/,
13/CD
]/)
and/CC
diabetes/VBZ
[/(
14/CD
,/,
15/CD
]/)
./.
====================
It/PRP
is/VBZ
therefore/RB
important/JJ
to/TO
understand/VB
the/DT
structure/NN
of/IN
this/DT
multi-enzyme/JJ
protein/NN
in/IN
order/NN
to/TO
suitably/RB
target/NN
its/PRP$
various/JJ
catalytic/JJ
domains/NNS
./.
====================
The/DT
resulting/VBG
ligands/NNS
could/MD
be/VB
potential/JJ
therapeutic/JJ
leads/VBZ
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
attempted/VBN
to/TO
predict/VB
the/DT
3D/NN
structure/NN
of/IN
the/DT
enoyl/NN
reductase/NN
(/(
ER/NN
)/)
and/CC
KR/NN
domains/NNS
of/IN
human/JJ
FASN/NN
in/IN
unbound/JJ
form/VBP
by/IN
comparative/JJ
modeling/VBG
./.
====================
At/IN
the/DT
time/NN
of/IN
this/DT
model/NN
development/NN
,/,
the/DT
structurally/RB
closest/JJS
template/NN
was/VBD
the/DT
reported/VBN
crystal/JJ
structure/NN
of/IN
porcine/NN
FASN/NN
(/(
PDB/NN
ID/NN
:/:
2VZ8/CD
,/,
3.2/CD
Å/NN
)/)
./.
====================
This/DT
mammalian/JJ
FASN/NN
template/NN
revealed/VBD
a/DT
complex/NN
architecture/NN
,/,
covering/VBG
five/CD
catalytic/JJ
domains/NNS
and/CC
also/RB
the/DT
inter-connecting/JJ
linkers/NNS
[/(
16/CD
]/)
./.
====================
The/DT
crystal/JJ
structures/NNS
of/IN
some/DT
of/IN
the/DT
other/JJ
individual/JJ
domains/NNS
of/IN
human/JJ
FASN/NN
were/VBD
available/JJ
in/IN
ligand-bound/JJ
forms-MAT/IN
(/(
PDB/NN
ID/NN
:/:
2JFK/CD
)/)
,/,
ACP/NN
(/(
PDB/NN
ID/NN
:/:
2CG5/CD
)/)
,/,
and/CC
TE/NN
(/(
PDB/NN
ID/NN
:/:
2PX6/CD
,/,
3TJM/NN
)/)
and/CC
in/IN
apo/NN
forms-KS/NNS
(/(
PDB/NN
ID/NN
:/:
3HHD/NN
)/)
and/CC
MAT/NN
(/(
PDB/NN
ID/NN
:/:
2JFD/CD
)/)
./.
====================
Most/JJS
recently/RB
,/,
crystal/JJ
structures/NNS
of/IN
human/JJ
FASN/NN
domains-ligand-bound/JJ
ER/NN
(/(
PDB/NN
ID/NN
:/:
4W9N/CD
)/)
and/CC
apo/NN
ER/NN
(/(
PDB/NN
ID/NN
:/:
4W82/CD
)/)
-and/CC
KR/NN
(/(
PDB/NN
ID/NN
:/:
4PIV/CD
)/)
have/VBP
been/VBN
reported/VBN
./.
====================
In/IN
order/NN
to/TO
validate/VB
the/DT
biological/JJ
closeness/RB
of/IN
the/DT
predicted/VBN
in/IN
silico/NN
model/NN
and/CC
also/RB
to/TO
infer/VB
the/DT
structure-function/JJ
relationships/NNS
,/,
the/DT
predicted/VBN
structures/NNS
here/RB
were/VBD
computationally/RB
docked/VBD
with/IN
their/PRP$
respective/JJ
physiological/JJ
substrates/NNS
./.
====================
Further/RB
,/,
these/DT
structures/NNS
were/VBD
also/RB
subjected/VBD
to/TO
molecular/JJ
dynamics/NNS
(/(
MD/NN
)/)
simulation/JJ
in/IN
apo/NN
and/CC
holo/JJ
conditions/NNS
to/TO
understand/VB
the/DT
conformational/JJ
dynamics/NNS
and/CC
stability/NN
./.
====================
The/DT
amino/NN
acid/NN
sequences/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
of/IN
human/JJ
FASN/NN
,/,
were/VBD
retrieved/VBN
from/IN
Uniprot/JJ
Kb/Swissprot/NN
server/RB
(/(
uniprot/JJ
ID/NN
:/:
P49327/NN
)/)
./.
====================
The/DT
sequences/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
were/VBD
229/CD
and/CC
255/CD
amino/NN
acids/NNS
in/IN
length/NN
,/,
respectively/RB
./.
====================
The/DT
retrieved/JJ
sequences/NNS
were/VBD
BLAST-analyzed/VBN
against/IN
PDB/NN
towards/IN
identifying/VBG
suitable/JJ
templates/NNS
for/IN
homology/NN
modeling/VBG
./.
====================
From/IN
the/DT
available/JJ
crystal/JJ
structures/NNS
deposited/JJ
in/IN
PDB/NN
during/IN
the/DT
time/NN
of/IN
this/DT
study/NN
(/(
early/JJ
2014/CD
)/)
,/,
the/DT
crystal/JJ
structure/NN
of/IN
mammalian/JJ
(/(
porcine/NN
,/,
Sus/NNP
scrofa/NN
)/)
fatty/JJ
acid/NN
synthase/NN
(/(
chain/NN
A/DT
,/,
PDB/NN
ID/NN
:/:
2VZ8/CD
)/)
showed/VBD
the/DT
closest/JJS
homology/NN
and/CC
was/VBD
therefore/RB
used/VBN
as/IN
the/DT
template/JJ
for/IN
modeling/VBG
the/DT
unbound/JJ
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
Homology/NN
modeling/VBG
of/IN
ER/NN
and/CC
KR/NN
domains/NNS
====================
The/DT
pairwise/JJ
sequence/NN
alignments/NNS
between/IN
the/DT
template/NN
and/CC
the/DT
targets/NNS
(/(
human/JJ
ER/NN
and/CC
KR/NN
)/)
were/VBD
built/RB
using/VBG
MODELLER/NN
9v7/CD
[/(
17/CD
,/,
18/CD
]/)
./.
====================
Further/RB
,/,
the/DT
aligned/JJ
target-template/NN
file/JJ
was/VBD
used/VBN
to/TO
generate/VB
homology/NN
models/NNS
./.
====================
A/DT
total/JJ
of/IN
100/CD
initial/JJ
models/NNS
were/VBD
generated/VBN
for/IN
both/DT
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
The/DT
qualities/NNS
of/IN
these/DT
models/NNS
were/VBD
ranked/VBN
based/VBN
on/IN
discrete/JJ
optimized/VBN
protein/NN
energy/NN
(/(
DOPE/NN
)/)
score/VBP
generated/VBN
by/IN
MODELER/NN
9v7/CD
[/(
17/CD
]/)
./.
====================
The/DT
models/NNS
showing/VBG
the/DT
lowest/JJS
DOPE/NN
score/RB
was/VBD
chosen/NN
as/IN
the/DT
best/JJS
model/NN
./.
====================
Further/RB
,/,
these/DT
best/IN
models/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
were/VBD
processed/VBN
using/VBG
the/DT
'Protein/JJ
Preparation/NN
Wizard/JJ
'/``
module/NN
of/IN
Schrodinger/NNP
Suite/JJ
(/(
Schrödinger/NNP
,/,
LLC/NN
,/,
New/JJ
York/NN
,/,
NY/NNP
,/,
USA/NNP
)/)
to/TO
correct/VB
the/DT
structural/JJ
defects/NNS
,/,
to/TO
add/VB
and/CC
optimize/VBP
hydrogen/NN
atoms/NNS
,/,
to/TO
assign/VB
bond/CC
orders/NNS
,/,
and/CC
also/RB
to/TO
selectively/RB
assign/VB
tautomerization/NN
and/CC
ionization/NN
states/NNS
./.
====================
Model/NN
validation/NN
====================
The/DT
validations/NNS
of/IN
structural/JJ
geometric/JJ
properties/NNS
,/,
like/IN
backbone/RB
conformation/NN
,/,
and/CC
of/IN
the/DT
compatibility/NN
of/IN
residue/NN
interactions/NNS
were/VBD
performed/VBN
using/VBG
the/DT
Structural/JJ
Analysis/NN
and/CC
Verification/NN
Server/NN
(/(
SAVES/NNS
;/:
http/RB
:/:
//nihserver.mbi.ucla.edu/SAVES/NNS
)/)
./.
====================
The/DT
Ramachandran/NN
plot/NN
statistics/NNS
determined/VBN
by/IN
the/DT
PROCHECK/NN
program/NN
(/(
analyzing/VBG
the/DT
phi/NN
[/(
Φ/NNP
]/)
and/CC
psi/NN
[/(
ψ/RB
]/)
torsion/NN
angles/NNS
)/)
were/VBD
used/VBN
to/TO
verify/VB
the/DT
backbone/NN
conformation/NN
and/CC
overall/JJ
stereochemical/JJ
quality/NN
of/IN
the/DT
protein/NN
structures/NNS
./.
====================
The/DT
non-bonded/JJ
atomic/JJ
interactions/NNS
of/IN
refined/VBN
structures/NNS
were/VBD
analyzed/VBN
using/VBG
the/DT
ERRAT/NN
program/NN
[/(
19/CD
]/)
./.
====================
Based/VBN
on/IN
the/DT
inferences/NNS
from/IN
the/DT
Ramachandran/NN
plot/NN
and/CC
ERRAT/NN
predictions/NNS
,/,
further/RB
refinement/JJ
of/IN
side/JJ
chain/NN
and/CC
backbone/NN
atoms/NNS
was/VBD
performed/VBN
using/VBG
MODREFINER/NN
[/(
20/CD
]/)
and/CC
was/VBD
subsequently/RB
loop-refined/VBD
using/VBG
MODELLER/NN
9v7/CD
scripts/NNS
./.
====================
Additionally/RB
,/,
these/DT
models/NNS
were/VBD
again/RB
refined/VBD
using/VBG
the/DT
WHATIF/NN
program/NN
[/(
21/CD
]/)
to/TO
remove/VB
atomic/JJ
clashes/NNS
(/(
bumps/NNS
)/)
by/IN
rotating/VBG
the/DT
side/JJ
chain/NN
torsion/NN
angles/NNS
(/(
chi1/NN
,/,
chi/NN
2/CD
,/,
and/CC
chi/NN
3/CD
)/)
./.
====================
Finally/RB
,/,
the/DT
quality/NN
and/CC
plausibility/NN
of/IN
the/DT
predicted/VBN
3D/NN
structures/NNS
were/VBD
validated/VBN
using/VBG
ProQ/NN
,/,
a/DT
model/NN
quality/NN
assessment/NN
program/NN
developed/VBD
by/IN
Wallner/NN
and/CC
Elofsson/NN
[/(
22/CD
]/)
./.
====================
MD/NN
simulation/NN
of/IN
homology/NN
models/NNS
====================
MD/NN
simulations/NNS
for/IN
the/DT
modeled/JJ
proteins/NNS
were/VBD
carried/VBN
out/RP
using/VBG
the/DT
Desmond/JJ
program/NN
,/,
an/DT
explicit/NN
solvent/JJ
MD/NN
package/NN
(/(
version/NN
3.1/CD
,/,
Desmond/CC
Molecular/JJ
Dynamics/NNS
System/NN
;/:
D./NNP
E./NNP
Shaw/NNP
Research/NNP
,/,
New/JJ
York/NN
,/,
NY/NNP
,/,
USA/NNP
and/CC
version/NN
3.1/CD
,/,
Maestro-Desmond/JJ
Interoperability/NN
Tools/NNS
;/:
Schrödinger/NNP
)/)
with/IN
inbuilt/JJ
optimized/VBN
potentials/NNS
for/IN
liquid/JJ
simulation/JJ
(/(
OPLS/NNS
2005/CD
)/)
force/VBP
field/NN
[/(
23/CD
]/)
./.
====================
The/DT
correctness/NN
of/IN
the/DT
chemical/JJ
structures/NNS
provided/VBD
to/TO
Desmond/JJ
was/VBD
ensured/VBN
using/VBG
Protein/NN
Preparation/NN
Wizard/JJ
(/(
macro/NN
models/NNS
)/)
,/,
Ligprep/JJ
(/(
chemical/JJ
molecules/NNS
)/)
,/,
and/CC
Epik/JJ
(/(
ligand/NN
protonation/NN
states/NNS
)/)
./.
====================
The/DT
system/NN
was/VBD
set/RB
up/IN
for/IN
simulation/JJ
using/VBG
a/DT
predefined/JJ
water/NN
model/NN
(/(
simple/JJ
point/NN
charge/JJ
,/,
SPC/NN
)/)
as/IN
solvent/JJ
in/IN
a/DT
cubic/JJ
box/NN
with/IN
periodic/JJ
boundary/NN
conditions/NNS
specifying/VBG
the/DT
shape/NN
and/CC
size/NN
of/IN
box/NN
as/IN
10/CD
Å/NN
×/CD
10/CD
Å/NN
×/CD
10/CD
Å/NN
distance/NN
./.
====================
The/DT
desirable/JJ
electrically/RB
neutral/JJ
system/NN
for/IN
simulation/JJ
was/VBD
built/JJ
with/IN
0.15/CD
M/NN
NaCl/NN
(/(
physiological/JJ
concentration/NN
of/IN
monovalent/JJ
ions/NNS
)/)
in/IN
10/CD
Å/NN
buffer/NN
using/VBG
the/DT
system-built/NN
option/NN
./.
====================
The/DT
relaxation/NN
of/IN
the/DT
system/NN
was/VBD
achieved/VBN
by/IN
implementing/VBG
Steepest/NN
Descent/JJ
and/CC
the/DT
limited-memory/JJ
Broyden-Fletcher-Goldfarb-Shanno/NN
algorithms/NNS
in/IN
a/DT
hybrid/NN
manner/NN
./.
====================
The/DT
simulation/JJ
was/VBD
performed/VBN
under/IN
NPT/NN
ensemble/JJ
for/IN
5/CD
ns/NNS
implementing/VBG
the/DT
Berendsen/JJ
thermostat/DT
and/CC
barostat/NN
methods/NNS
./.
====================
A/DT
constant/JJ
temperature/NN
of/IN
300/CD
K/NN
was/VBD
maintained/VBN
throughout/IN
the/DT
simulation/JJ
using/VBG
the/DT
Nose-Hoover/NN
thermostat/DT
algorithm/NN
[/(
24/CD
]/)
and/CC
Martyna-Tobias-Klein/NN
Barostat/NN
algorithm/NN
[/(
25/CD
]/)
to/TO
maintain/VB
1/CD
atm/NN
of/IN
pressure/NN
,/,
respectively/RB
./.
====================
The/DT
short-range/JJ
coulombic/JJ
interactions/NNS
were/VBD
analyzed/VBN
using/VBG
a/DT
cut-off/JJ
value/NN
of/IN
9.0/CD
Å/NN
using/VBG
the/DT
short-range/NN
method/NN
./.
====================
The/DT
smooth/JJ
particle/NN
mesh/JJ
ewald/JJ
method/NN
[/(
26/CD
]/)
was/VBD
used/VBN
for/IN
handling/NN
long-range/JJ
coulombic/JJ
interactions/NNS
./.
====================
Tolerance/NN
value/NN
usually/RB
affects/VBZ
the/DT
accuracy/NN
of/IN
long-range/JJ
interactions/NNS
;/:
therefore/RB
,/,
a/DT
smaller/JJR
value/NN
of/IN
1e-9/NN
is/VBZ
set/NN
for/IN
accurate/JJ
computations/NNS
implemented/JJ
by/IN
the/DT
SHAKE/NN
algorithm/NN
./.
====================
The/DT
final/JJ
production/NN
run/JJ
was/VBD
carried/VBN
out/RP
for/IN
5/CD
ns/NNS
,/,
and/CC
the/DT
trajectory/JJ
sampling/NN
was/VBD
done/VBN
at/IN
an/DT
interval/JJ
of/IN
1.0/CD
ps/NNS
[/(
23/CD
]/)
./.
====================
Binding/NN
pocket/NN
prediction/NN
====================
Site/NN
Map/NN
2.6/CD
(/(
Schrödinger/NNP
,/,
LLC/NN
)/)
was/VBD
used/VBN
to/TO
identify/VB
the/DT
active/JJ
sites/NNS
on/IN
the/DT
predicted/VBN
models/NNS
./.
====================
Various/JJ
countermaps/NNS
were/VBD
also/RB
generated/VBD
to/TO
distinguish/VB
the/DT
hydrophobic/JJ
and/CC
hydrophilic/JJ
regions/NNS
on/IN
the/DT
active/JJ
site/NN
regions/NNS
./.
====================
Finally/RB
,/,
the/DT
best/JJS
binding/VBG
pockets/NNS
were/VBD
ranked/VBN
based/VBN
on/IN
the/DT
Sitemap/NN
score/RB
./.
====================
Substrate/NN
docking/NN
and/CC
postdocking/JJ
simulation/NN
====================
The/DT
substrates/NNS
for/IN
the/DT
ER/NN
and/CC
KR/NN
domains-namely/RB
,/,
the/DT
trans/JJ
butenoyl/NN
and/CC
β-ketobutyryl/NN
groups-were/VBD
sketched/JJ
using/VBG
the/DT
2D/NN
draw/VB
tool/NN
(/(
version/NN
9.3/CD
,/,
Maestro/NNP
;/:
Schrödinger/NNP
,/,
LLC/NN
)/)
./.
====================
The/DT
optimal/JJ
3D/NN
structures/NNS
of/IN
the/DT
sketched/JJ
substrates/NNS
were/VBD
generated/VBN
using/VBG
Ligprep/JJ
Module/JJ
,/,
which/WDT
fixes/NNS
ionization/NN
states/NNS
,/,
tautomers/NNS
,/,
and/CC
other/JJ
stereochemical/JJ
errors/NNS
./.
====================
The/DT
correct/JJ
chiral/JJ
forms/NNS
of/IN
the/DT
optimized/VBN
substrates/NNS
were/VBD
used/VBN
for/IN
docking/NN
with/IN
the/DT
corresponding/JJ
FASN/NN
domains/NNS
./.
====================
Receptor/NN
grid/NN
files/NNS
for/IN
glide/NN
docking/NN
were/VBD
generated/VBN
to/TO
cover/VB
the/DT
volume/NN
of/IN
the/DT
predicted/VBN
active/JJ
sites/NNS
./.
====================
Here/RB
,/,
van/NN
der/NN
Waals/NNS
radius/NN
is/VBZ
scaled/VBN
to/TO
1.0/CD
with/IN
a/DT
partial/JJ
cut-off/JJ
of/IN
0.25/CD
to/TO
soften/JJ
the/DT
potential/JJ
for/IN
non-polar/JJ
parts/NNS
of/IN
a/DT
receptor/NN
,/,
where/WRB
other/JJ
atoms/NNS
are/VBP
free/JJ
of/IN
scaling/VBG
./.
====================
The/DT
receptor/NN
grid/NN
file/JJ
and/CC
the/DT
prepared/VBN
substrate/NN
were/VBD
docked/VBN
using/VBG
Glide/NN
standard/JJ
precision/NN
,/,
where/WRB
the/DT
ligand/NN
sampling/NN
was/VBD
set/NN
to/TO
be/VB
flexible/JJ
,/,
ensuring/VBG
the/DT
sample/JJ
ring/NN
conformation/NN
and/CC
nitrogen/NN
inversions/NNS
./.
====================
Ligands/NNS
were/VBD
set/RB
to/TO
select/VB
only/RB
less/RBR
than/IN
300/CD
atoms/NNS
and/CC
less/RBR
than/IN
50/CD
rotatable/JJ
bonds/NNS
with/IN
a/DT
van/NN
der/NN
Waals/NNS
scaling/VBG
factor/NN
of/IN
0.8/CD
with/IN
a/DT
partial/JJ
cut-off/JJ
of/IN
0.15/CD
./.
====================
Out/DT
of/IN
the/DT
1,000/CD
poses/VBZ
generated/VBN
per/IN
docking/NN
run/NN
,/,
10/CD
energetically/RB
favorable/JJ
poses/VBZ
per/FW
ligand/NN
were/VBD
selected/VBN
./.
====================
Glide/NN
score/RB
,/,
an/DT
empirical/JJ
docking/NN
scoring/VBG
function/NN
that/IN
implements/VBZ
the/DT
OPLS/NN
2005/CD
force/VBP
field/NN
,/,
was/VBD
used/VBN
to/TO
infer/VB
the/DT
affinity/NN
and/CC
binding/NN
mode/NN
of/IN
the/DT
substrate/NN
./.
====================
The/DT
best/JJS
docked/VBD
substrate/NN
conformation/NN
for/IN
the/DT
ER/NN
and/CC
KR/NN
(/(
holo/JJ
)/)
domains/NNS
was/VBD
subjected/VBN
to/TO
MD/NN
simulation/JJ
for/IN
5/CD
ns/NNS
,/,
similar/JJ
to/TO
that/DT
of/IN
the/DT
methods/NNS
discussed/VBN
for/IN
MD/NN
simulations/NNS
of/IN
the/DT
apo/NN
form/VBP
,/,
except/IN
that/IN
maximum/JJ
iterations/NNS
of/IN
2,000/CD
steps/NNS
were/VBD
applied/VBN
on/IN
solute/JJ
heavy/JJ
atoms/NNS
alone/RB
with/IN
a/DT
convergence/NN
threshold/RB
as/IN
1.0/CD
kcal/mol/Å/JJ
./.
====================
Target-template/NN
alignment/NN
====================
The/DT
amino/NN
acid/NN
sequences/NNS
of/IN
the/DT
human/JJ
FASN/NN
ER/NN
and/CC
KR/NN
domains/NNS
were/VBD
retrieved/VBN
from/IN
Uniprot/JJ
(/(
P49327/NN
)/)
./.
====================
Comparative/JJ
modeling/VBG
method/NN
was/VBD
implemented/VBN
to/TO
predict/VB
the/DT
structures/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
The/DT
structural/JJ
templates/NNS
for/IN
modeling/VBG
the/DT
query/NN
sequences/NNS
were/VBD
searched/VBN
against/IN
PDB/NN
using/VBG
BLASTP/NN
./.
====================
Many/JJ
of/IN
the/DT
hits/NNS
obtained/VBN
were/VBD
similar/JJ
to/TO
the/DT
query/NN
sequences/NNS
,/,
mainly/RB
representing/VBG
the/DT
reductase/NN
families/NNS
./.
====================
The/DT
best/JJS
templates/NNS
were/VBD
selected/VBN
in/IN
accordance/NN
with/IN
the/DT
optimal/JJ
pairwise/JJ
alignment/NN
,/,
sequence/NN
coverage/VBP
,/,
and/CC
sequence/NN
conservation/NN
./.
====================
Accordingly/RB
,/,
mammalian/JJ
(/(
porcine/NN
,/,
Sus/NN
scrofa/NN
)/)
fatty/JJ
acid/NN
synthase/NN
(/(
chain/NN
A/DT
)/)
(/(
PDB/NN
ID/NN
:/:
2VZ8/CD
,/,
3.2/CD
Å/NNP
resolution/NN
,/,
region/NN
1635/CD
to/TO
1860/CD
,/,
82/CD
%/NN
similarity/NN
)/)
was/VBD
chosen/NN
for/IN
ER/NN
./.
====================
Similarly/RB
,/,
the/DT
template/NN
chosen/NN
for/IN
the/DT
KR/NN
domain/NN
(/(
porcine/NN
,/,
Sus/NN
scrofa/NN
)/)
showed/VBD
significant/JJ
homology/NN
(/(
83/CD
%/NN
of/IN
sequence/NN
identity/NN
matching/VBG
to/TO
region/NN
1866/CD
to/TO
2117/CD
of/IN
2VZ8/CD
)/)
and/CC
was/VBD
used/VBN
for/IN
modeling/VBG
the/DT
KR/NN
domain/NN
./.
====================
Homology/NN
modeling/VBG
====================
We/PRP
had/VBD
attempted/VBN
to/TO
model/VB
the/DT
protein/NN
structure/NN
of/IN
human/JJ
FASN/NN
ER/NN
domain/NN
earlier/RBR
for/IN
the/DT
purpose/NN
of/IN
understanding/VBG
its/PRP$
bonding/VBG
interactions/NNS
with/IN
the/DT
known/JJ
inhibitor/NN
triclosan/NN
[/(
27/CD
]/)
./.
====================
There/EX
was/VBD
a/DT
close/JJ
correlation/NN
between/IN
the/DT
inhibition/NN
constant/JJ
(/(
Ki/NN
)/)
obtained/VBN
from/IN
the/DT
in/FW
silico/NN
model/NN
and/CC
the/DT
experimentally/RB
obtained/VBN
biochemical/JJ
IC50/NN
./.
====================
However/RB
,/,
in/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
implemented/VBD
advanced/JJ
algorithms/NNS
and/CC
MD/NN
simulations/NNS
to/TO
provide/VB
a/DT
more/RBR
refined/VBN
and/CC
highly/RB
plausible/JJ
structure/NN
,/,
with/IN
more/RBR
emphasis/NN
on/IN
the/DT
catalytic/JJ
active/JJ
site/NN
./.
====================
As/IN
discussed/VBN
above/IN
,/,
the/DT
crystal/JJ
structure/NN
of/IN
Sus/JJ
scrofa/NN
FASN/NN
(/(
PDB/NN
ID/NN
2VZ8/CD
)/)
was/VBD
used/VBN
as/IN
the/DT
template/NN
to/TO
model/VB
the/DT
3D/NN
structures/NNS
of/IN
the/DT
human/JJ
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
The/DT
pairwise/JJ
sequence/NN
alignment/NN
between/IN
the/DT
template/NN
and/CC
targets/NNS
were/VBD
built/JJ
using/VBG
MODELLER/NN
9v7/CD
./.
====================
The/DT
best/JJS
models/NNS
for/IN
the/DT
human/JJ
ER/NN
and/CC
KR/NN
domains/NNS
were/VBD
chosen/NN
based/VBN
on/IN
the/DT
lowest/JJS
DOPE/NN
score/RB
./.
====================
Further/RB
,/,
these/DT
models/NNS
were/VBD
found/VBN
to/TO
have/VB
similar/JJ
secondary/JJ
structures/NNS
(/(
folds/VBZ
and/CC
loops/VBZ
)/)
when/WRB
compared/VBN
with/IN
that/DT
of/IN
the/DT
template/NN
./.
====================
The/DT
backbone/NN
alignment/NN
score/RB
was/VBD
generated/VBN
using/VBG
maestro/FW
(/(
version/NN
9.3/CD
,/,
Maestro/FW
,/,
Schrödinger/NNP
,/,
LLC/NN
)/)
,/,
superimposing/VBG
the/DT
respective/JJ
templates/NNS
./.
====================
The/DT
alignment/NN
scores/VBZ
were/VBD
found/VBN
to/TO
be/VB
0.27/CD
for/IN
modeled/JJ
human/JJ
ER/NN
and/CC
0.01/CD
for/IN
modeled/JJ
KR/NN
domain/NN
./.
====================
In/IN
the/DT
postmodel/JJ
development/NN
,/,
we/PRP
also/RB
compared/VBD
our/PRP$
predicted/VBN
structures/NNS
with/IN
the/DT
very/RB
recently/RB
reported/VBN
crystal/JJ
structures/NNS
of/IN
the/DT
human/JJ
ER/NN
(/(
4W82/CD
)/)
and/CC
KR/NN
domains/NNS
(/(
4PIV/CD
)/)
[/(
28/CD
,/,
29/CD
]/)
,/,
wherein/IN
the/DT
alignment/JJ
scores/VBZ
were/VBD
found/VBN
to/TO
be/VB
0.28/CD
and/CC
0.048/CD
for/IN
modeled/JJ
ER/NN
and/CC
KR/NN
,/,
respectively/RB
./.
====================
Generally/RB
,/,
the/DT
lower/JJR
alignment/NN
score/RB
(/(
less/RBR
than/IN
0.7-0.8/CD
)/)
is/VBZ
indicative/JJ
of/IN
a/DT
good/JJ
alignment/NN
and/CC
higher/JJR
structurally/RB
identity/NN
,/,
according/VBG
to/TO
Yang/NN
and/CC
Honig/NN
[/(
30/CD
]/)
./.
====================
Hence/RB
,/,
taken/VBN
together/RB
,/,
all/DT
of/IN
these/DT
findings/NNS
imply/VBP
the/DT
predictive/JJ
accuracy/NN
of/IN
the/DT
in/FW
silico/NN
methods/NNS
implemented/JJ
here/RB
./.
====================
The/DT
predicted/VBN
structure/NN
of/IN
the/DT
human/JJ
ER/NN
domain/NN
showed/VBD
a/DT
Rossmann/JJ
fold/JJ
at/IN
region/NN
1651/CD
to/TO
1794/CD
,/,
which/WDT
harbors/VBZ
a/DT
nucleotide/JJ
binding/NN
cavity/NN
(/(
1671/CD
to/TO
1688/CD
)/)
and/CC
also/RB
overlapping/VBG
substrate/NN
binding/VBG
cavities/NNS
at/IN
1650-1653/CD
and/CC
1795-1863/CD
,/,
as/IN
proposed/VBN
by/IN
Maier/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
./.
====================
Similarly/RB
,/,
the/DT
predicted/VBN
structure/NN
of/IN
the/DT
KR/NN
domain/NN
showed/VBD
a/DT
binding/VBG
cavity/NN
at/IN
the/DT
region/NN
covering/VBG
1864/CD
to/TO
2117/CD
./.
====================
The/DT
active/JJ
cavity/NN
residue/NN
Lys1995/NN
and/CC
the/DT
nucleotide/NN
binding/NN
residues/NNS
1886-1901/CD
[/(
16/CD
]/)
were/VBD
found/VBN
to/TO
harbor/VB
the/DT
predicted/VBN
binding/NN
cavity/NN
./.
====================
The/DT
overall/JJ
topology/NN
and/CC
secondary/JJ
structure/NN
information/NN
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
are/VBP
shown/VBN
in/IN
Figs/NNS
./.
====================
1/CD
and/CC
2/CD
./.
====================
Secondary/JJ
structure/NN
analysis/NN
====================
PDBsum/NN
server/RB
,/,
which/WDT
uses/VBZ
Gail/NN
Hutchinson/NN
's/POS
PROMOTIF/NN
program/NN
to/TO
compute/VB
the/DT
secondary/JJ
structure/NN
motif/NN
information/NN
of/IN
the/DT
models/NNS
generated/VBN
(/(
http/NN
:/:
//www.ebi.ac.uk/pdbsum//JJ
)/)
,/,
was/VBD
used/VBN
to/TO
predict/VB
the/DT
topology/NN
of/IN
the/DT
predicted/VBN
structures/NNS
./.
====================
The/DT
overall/JJ
secondary/JJ
structure/NN
elements/NNS
of/IN
the/DT
ER/NN
domain/NN
include/VBP
18.8/CD
%/NN
of/IN
residues/NNS
forming/VBG
strands/NNS
,/,
44.5/CD
%/NN
forming/VBG
alpha/NN
helices/VBZ
,/,
0.9/CD
%/NN
forming/VBG
3-10/CD
helices/VBZ
,/,
and/CC
35.5/CD
%/NN
of/IN
residues/NNS
forming/VBG
other/JJ
structures/NNS
./.
====================
Similarly/RB
,/,
secondary/JJ
structure/NN
elements/NNS
of/IN
the/DT
KR/NN
domain/NN
include/VBP
16.1/CD
%/NN
of/IN
residues/NNS
forming/VBG
strands/NNS
,/,
35.7/CD
%/NN
forming/VBG
alpha/NN
helices/VBZ
,/,
0.0/CD
%/NN
forming/VBG
3-10/CD
helices/VBZ
,/,
and/CC
48.2/CD
%/NN
of/IN
residues/NNS
forming/VBG
other/JJ
structures/NNS
./.
====================
The/DT
ER/NN
model/NN
has/VBZ
2/CD
beta-sheets/NNS
,/,
5/CD
beta-alpha-beta/NN
motifs/NNS
,/,
1/CD
beta/NN
bulge/JJ
,/,
8/CD
strands/NNS
,/,
12/CD
helices/VBZ
,/,
12/CD
helix-helix/NN
interactions/NNS
,/,
and/CC
10/CD
beta/NN
turns/NNS
./.
====================
Similarly/RB
,/,
the/DT
KR/NN
domain/NN
has/VBZ
2/CD
beta-sheets/NNS
,/,
4/CD
beta-alpha-beta/NN
motifs/NNS
,/,
1/CD
beta/NN
bulge/JJ
,/,
9/CD
strands/NNS
,/,
7/CD
helices/VBZ
,/,
5/CD
helix-helix/NN
interactions/NNS
,/,
19/CD
beta/NN
turns/NNS
,/,
and/CC
2/CD
gamma/NN
turns/NNS
./.
====================
Model/NN
validation/NN
====================
The/DT
initial/JJ
models/NNS
were/VBD
subjected/VBN
to/TO
different/JJ
structure/NN
evaluation/NN
tools/NNS
for/IN
understanding/VBG
the/DT
geometries/NNS
,/,
backbone/RB
configuration/NN
,/,
dihedrals/NNS
,/,
and/CC
residue-residue/NN
interactions/NNS
./.
====================
The/DT
Ramachandran/NN
plot/NN
for/IN
the/DT
ER/NN
domain/NN
showed/VBD
0.5/CD
%/NN
residues/NNS
in/IN
a/DT
disallowed/JJ
region/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
KR/NN
domain/NN
,/,
0.0/CD
%/NN
of/IN
the/DT
residues/NNS
were/VBD
in/IN
disallowed/JJ
regions/NNS
./.
====================
Hence/RB
,/,
these/DT
models/NNS
were/VBD
further/RB
refined/VBD
using/VBG
the/DT
WHAT/NN
IF/NN
program/NN
to/TO
remove/VB
the/DT
atomic/JJ
bumps/NNS
and/CC
subsequently/RB
loop-refined/VBD
using/VBG
MODELLER/NN
9v7/CD
scripts/NNS
and/CC
the/DT
MODREFINER/NN
algorithm/NN
./.
====================
The/DT
final/JJ
refined/VBD
structures/NNS
of/IN
both/DT
domains/NNS
showed/VBD
no/DT
residues/NNS
in/IN
the/DT
disallowed/JJ
region/NN
of/IN
the/DT
Ramachandran/NN
plot/NN
(/(
Figs/NNS
./.
====================
3/CD
and/CC
4/CD
)/)
./.
====================
The/DT
overall/JJ
stereochemical/JJ
parameters/NNS
for/IN
the/DT
modeled/JJ
proteins/NNS
were/VBD
measured/VBN
using/VBG
G-factor/NN
and/CC
ERRAT/NN
calculations/NNS
by/IN
PROCHECK/NN
./.
====================
G-factor/NN
is/VBZ
a/DT
measure/JJ
of/IN
the/DT
proper/JJ
dihedrals/NNS
and/CC
covalent/JJ
bond/NN
orders/NNS
,/,
and/CC
it/PRP
is/VBZ
expressed/VBN
overall/JJ
as/IN
log-odd/JJ
score/RB
./.
====================
G-factor/NN
scores/VBZ
for/IN
optimal/JJ
structures/NNS
range/NN
from/IN
0.0/CD
to/TO
0.1/CD
with/IN
increasing/VBG
order/NN
of/IN
confidence/NN
./.
====================
A/DT
negative/JJ
G-factor/NN
score/RB
indicates/VBZ
improper/IN
conformation/NN
of/IN
the/DT
residues/NNS
,/,
while/IN
higher/JJR
positive/JJ
scores/NNS
indicate/VBP
proper/JJ
conformation/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
predicted/VBN
model/NN
of/IN
the/DT
ER/NN
domain/NN
,/,
the/DT
overall/JJ
log-odd/NN
score/RB
was/VBD
found/VBN
to/TO
be/VB
0.30/CD
,/,
which/WDT
indicates/VBZ
a/DT
high/JJ
plausibility/NN
of/IN
the/DT
structure/NN
with/IN
negligible/JJ
improper/NN
conformations/NNS
./.
====================
Similarly/RB
,/,
the/DT
KR/NN
model/NN
also/RB
showed/VBD
an/DT
overall/JJ
G-factor/NN
score/RB
of/IN
0.22/CD
,/,
suggestive/JJ
of/IN
a/DT
high/JJ
plausibility/NN
of/IN
the/DT
structure/NN
./.
====================
Moreover/RB
,/,
the/DT
non-bonded/JJ
atomic/JJ
interactions/NNS
of/IN
the/DT
models/NNS
were/VBD
analyzed/VBN
using/VBG
the/DT
ERRAT/NN
tool/NN
,/,
wherein/IN
the/DT
overall/JJ
quality/NN
score/RB
for/IN
the/DT
predicted/VBN
structures/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
were/VBD
found/VBN
to/TO
be/VB
95.92/CD
and/CC
80.85/CD
,/,
respectively/RB
./.
====================
The/DT
ERRAT/NN
scores/VBZ
for/IN
both/DT
models/NNS
were/VBD
above/JJ
50/CD
and/CC
are/VBP
considered/VBN
a/DT
standard/JJ
for/IN
good/JJ
models/NNS
./.
====================
To/TO
validate/VB
this/DT
further/JJ
,/,
the/DT
modeled/JJ
structures/NNS
were/VBD
also/RB
assessed/VBN
for/IN
their/PRP$
quality/NN
using/VBG
the/DT
ProQ/NN
server/RB
./.
====================
ProQ/NN
assessment/NN
for/IN
the/DT
ER/NN
model/NN
predicted/VBN
the/DT
LGscore/JJ
to/TO
be/VB
4.362/CD
(/(
>/JJR
4.0/CD
,/,
extremely/RB
good/JJ
model/NN
)/)
and/CC
the/DT
MaxSub/NN
score/RB
to/TO
be/VB
0.416/CD
(/(
>/JJR
0.1/CD
,/,
fairly/RB
good/JJ
model/NN
)/)
./.
====================
Similarly/RB
,/,
for/IN
the/DT
KR/NN
domain/NN
,/,
the/DT
LGscore/JJ
was/VBD
3.509/CD
(/(
>/JJR
2.5/CD
,/,
very/RB
good/JJ
model/NN
)/)
and/CC
the/DT
MaxSub/NN
score/RB
was/VBD
0.246/CD
(/(
>/JJR
0.1/CD
,/,
fairly/RB
good/JJ
model/NN
)/)
,/,
suggesting/VBG
higher/JJR
plausibility/NN
of/IN
the/DT
models/NNS
./.
====================
MD/NN
simulation/NN
====================
MD/NN
simulation/JJ
was/VBD
carried/VBN
out/RP
for/IN
the/DT
predicted/VBN
models/NNS
to/TO
understand/VB
the/DT
stability/NN
and/CC
conformational/JJ
changes/NNS
of/IN
the/DT
modeled/JJ
proteins/NNS
in/IN
holo/JJ
and/CC
apo/NN
forms/NNS
./.
====================
The/DT
simulation/JJ
was/VBD
carried/VBN
out/RP
in/IN
a/DT
water/NN
(/(
SPC-molecule/NN
)/)
-solvated/JJ
system/NN
with/IN
optimal/JJ
physiological/JJ
conditions/NNS
,/,
wherein/IN
the/DT
temperature/NN
and/CC
pressure/NN
were/VBD
maintained/VBN
at/IN
300/CD
K/NN
and/CC
1/CD
atm/NN
for/IN
both/DT
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
The/DT
computed/JJ
total/JJ
energy/NN
and/CC
potential/JJ
energy/NN
remained/VBD
stable/JJ
from/IN
start/NN
of/IN
the/DT
dynamics/NNS
simulation/JJ
until/IN
the/DT
course/NN
of/IN
the/DT
the/DT
5-ns/NNS
simulation/JJ
in/IN
the/DT
case/NN
of/IN
both/DT
proteins/NNS
./.
====================
The/DT
ER/NN
domain/NN
had/VBD
a/DT
total/JJ
energy/NN
of/IN
-82,181.468/CD
kJ/mol/NN
and/CC
a/DT
potential/JJ
energy/NN
of/IN
-101,788.978/CD
kJ/mol/NN
./.
====================
Similarly/RB
,/,
KR/NN
also/RB
had/VBD
stable/JJ
distribution/NN
with/IN
a/DT
total/JJ
energy/NN
of/IN
-141,285.655/CD
kJ/mol/NN
and/CC
potential/JJ
energy/NN
of/IN
-174,168.487/CD
kJ/mol/NN
./.
====================
The/DT
event/NN
trajectory/JJ
was/VBD
observed/VBN
to/TO
remain/VB
stable/JJ
throughout/IN
the/DT
simulation/JJ
process/NN
./.
====================
Further/RB
,/,
the/DT
stability/NN
of/IN
the/DT
modeled/JJ
proteins/NNS
was/VBD
verified/VBN
by/IN
plotting/VBG
the/DT
root/NN
mean/NN
square/VBP
deviation/NN
(/(
RMSD/NN
)/)
graph/NN
for/IN
backbone/NN
atoms/NNS
during/IN
the/DT
production/NN
run/JJ
./.
====================
The/DT
RMSD/NN
for/IN
the/DT
ER/NN
domain/NN
remained/VBD
stable/JJ
for/IN
the/DT
5-ns/NNS
time/NN
frame/NN
with/IN
minimal/JJ
deviation/NN
until/IN
the/DT
end/NN
of/IN
5/CD
ns/NNS
(/(
Fig/NN
./.
====================
5A/CD
)/)
./.
====================
Similarly/RB
,/,
the/DT
RMSD/NN
plot/NN
for/IN
the/DT
KR/NN
model/NN
also/RB
suggested/VBD
a/DT
stable/JJ
trajectory/JJ
during/IN
the/DT
production/NN
run/JJ
(/(
Fig/NN
./.
====================
6A/CD
)/)
./.
====================
Moreover/RB
,/,
the/DT
radius/NN
of/IN
gyration/NN
was/VBD
also/RB
calculated/VBN
for/IN
each/DT
model/NN
during/IN
the/DT
simulation/JJ
process/NN
and/CC
was/VBD
found/VBN
to/TO
be/VB
within/IN
the/DT
range/NN
of/IN
1/CD
Å/NN
,/,
indicating/VBG
the/DT
compactness/NN
of/IN
the/DT
models/NNS
predicted/VBN
(/(
Figs/NNS
./.
====================
5B/NN
and/CC
6B/NN
)/)
./.
====================
Hence/RB
,/,
these/DT
validation/NN
studies/NNS
summarize/VBP
the/DT
higher/JJR
plausibility/NN
of/IN
the/DT
predicted/VBN
models/NNS
./.
====================
Active/JJ
site/NN
prediction/NN
====================
Site/NN
Map/NN
2.6/CD
(/(
Schrödinger/NNP
,/,
LLC/NN
)/)
was/VBD
used/VBN
to/TO
predict/VB
the/DT
active/JJ
sites/NNS
in/IN
the/DT
modeled/JJ
proteins/NNS
./.
====================
The/DT
presently/RB
modeled/VBN
human/JJ
FASN/NN
ER/NN
domain/NN
comprises/VBZ
two/CD
subdomains/NNS
forming/VBG
the/DT
Rossmann/NN
fold/JJ
and/CC
substrate/NN
binding/NN
fold/JJ
./.
====================
According/VBG
to/TO
Maier/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
,/,
on/IN
the/DT
porcine/NN
ER/NN
structure/NN
,/,
NADP+/NN
is/VBZ
likely/JJ
to/TO
be/VB
found/VBN
in/IN
the/DT
junction/NN
of/IN
the/DT
subdomains/NNS
,/,
and/CC
Lys1771/NN
and/CC
Asp1797/NN
may/MD
be/VB
donor/NN
residues/NNS
for/IN
substrate/NN
protonation/NN
./.
====================
This/DT
orientation/NN
favors/VBZ
the/DT
entry/NN
of/IN
substrate/NN
through/IN
a/DT
tunnel/NN
to/TO
the/DT
nicotinamide/NN
ring/NN
and/CC
its/PRP$
exit/VBP
through/IN
an/DT
opening/VBG
at/IN
the/DT
posterior/JJ
part/NN
of/IN
the/DT
ER/NN
domain/NN
[/(
16/CD
]/)
./.
====================
This/DT
fold/JJ
orientation/NN
was/VBD
observed/VBN
in/IN
our/PRP$
predicted/VBN
model/NN
of/IN
ER/NN
(/(
Fig/NN
./.
====================
7/CD
)/)
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
KR/NN
domain/NN
,/,
the/DT
predicted/VBN
active/JJ
site/NN
had/VBD
Lys1995/NN
as/IN
a/DT
central/JJ
key/JJ
substrate-interacting/VBG
residue/NN
surrounded/VBD
by/IN
Asn2038/NN
,/,
Tyr2034/NN
,/,
and/CC
Ser2021residues/NNS
,/,
which/WDT
also/RB
coincides/VBZ
with/IN
the/DT
observations/NNS
of/IN
Maier/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
on/IN
porcine/NN
KR/NN
./.
====================
Docking/VBG
and/CC
post-docking/JJ
simulation/NN
====================
Normally/RB
,/,
in/IN
FASN-catalyzed/JJ
lipid/NN
biosynthesis/NN
,/,
seven/CD
cycles/NNS
of/IN
two/CD
carbon/JJ
additions/NNS
are/VBP
essential/JJ
for/IN
synthesizing/VBG
the/DT
16-carbon/JJ
palmitate/NN
./.
====================
The/DT
respective/JJ
initial/JJ
physiological/JJ
substrates/NNS
for/IN
the/DT
KR/NN
and/CC
ER/NN
domains-namely/RB
,/,
β-ketobutyryl/NN
and/CC
trans/JJ
butenoyl/NN
groups-were/VBD
built/NN
using/VBG
2D/JJ
draw/VB
./.
====================
Further/RB
,/,
these/DT
structures/NNS
were/VBD
optimized/VBN
using/VBG
LigPrep/JJ
2.6/CD
(/(
Schrödinger/NNP
,/,
LLC/NN
)/)
and/CC
docked/VBD
to/TO
the/DT
respective/JJ
catalytic/JJ
active/JJ
sites/NNS
using/VBG
Glide/NN
5.8/CD
(/(
Schrödinger/NNP
,/,
LLC/NN
)/)
(/(
Figs/NNS
./.
====================
8/CD
and/CC
9/CD
)/)
./.
====================
Reports/NNS
suggest/VBP
that/IN
in/IN
these/DT
β-carbon/JJ
processing/NN
enzymes/NNS
,/,
KR/NN
and/CC
ER/NN
have/VBP
been/VBN
studied/VBN
using/VBG
derivatives/NNS
of/IN
S-β-ketobutyryl/NN
and/CC
S-crotonyl/NN
(/(
S-acyl-N-acetyl/NN
cysteamine/NN
thioester/DT
derivatives/NNS
)/)
as/IN
model/NN
substrates/NNS
[/(
3/CD
,/,
31/CD
]/)
./.
====================
The/DT
Glide/NN
docking/NN
score/RB
for/IN
the/DT
ER/NN
trans/JJ
butenoyl/NN
complex/NN
was/VBD
found/VBN
to/TO
be/VB
-2.283/CD
kcal/mol/NN
with/IN
a/DT
Glide/NN
energy/NN
of/IN
-11.638/CD
kcal/mol/NN
./.
====================
Similarly/RB
,/,
the/DT
Glide/NN
docking/NN
score/RB
for/IN
the/DT
KR/NN
domain/NN
was/VBD
found/VBN
to/TO
be/VB
-5.25738/CD
kcal/mol/NN
with/IN
a/DT
Glide/NN
energy/NN
of/IN
-16.827/CD
kcal/mol/NN
./.
====================
Finally/RB
,/,
both/CC
docked/VBD
complexes/NNS
were/VBD
validated/VBN
for/IN
the/DT
stability/NN
of/IN
complex/NN
formation/NN
,/,
implementing/VBG
a/DT
MD/NN
simulation/JJ
using/VBG
DESMOND/NN
./.
====================
The/DT
simulations/NNS
for/IN
both/DT
holoenzyme/NN
complexes/NNS
were/VBD
carried/VBN
out/RP
for/IN
5/CD
ns/NNS
./.
====================
The/DT
RMSD/NN
plot/NN
for/IN
all/DT
atoms/NNS
of/IN
each/DT
holoenzyme/NN
during/IN
the/DT
production/NN
run/JJ
was/VBD
analyzed/VBN
./.
====================
The/DT
plots/NNS
showed/VBD
no/DT
significant/JJ
increase/NN
in/IN
deviation/NN
until/IN
the/DT
completion/NN
of/IN
5/CD
ns/NNS
(/(
Figs/NNS
./.
====================
5A/CD
and/CC
6A/NN
)/)
./.
====================
Similarly/RB
,/,
the/DT
radius/NN
of/IN
gyration/NN
was/VBD
also/RB
calculated/VBN
for/IN
the/DT
complex/NN
structures/NNS
,/,
which/WDT
inferred/VBD
the/DT
compactness/NN
of/IN
the/DT
docked/VBN
complexes/NNS
,/,
as/IN
it/PRP
was/VBD
within/IN
the/DT
range/NN
of/IN
1/CD
Å/NN
in/IN
the/DT
case/NN
of/IN
both/DT
complexes/NNS
./.
====================
Hence/RB
,/,
all/DT
of/IN
these/DT
findings/NNS
strongly/RB
suggest/VBP
the/DT
highly/RB
stable/JJ
complex/NN
formation/NN
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
with/IN
their/PRP$
respective/JJ
substrates/NNS
(/(
Figs/NNS
./.
====================
5B/NN
and/CC
6B/NN
)/)
./.
====================
The/DT
root/NN
mean/NN
square/NN
fluctuation/NN
plot/NN
of/IN
all/DT
residues/NNS
on/IN
pre-substrate/NN
binding/NN
and/CC
post-substrate/JJ
binding/NN
(/(
Fig/NN
./.
====================
10A/CD
and/CC
10B/NN
)/)
clearly/RB
indicates/VBZ
the/DT
decrease/NN
in/IN
overall/JJ
flexibility/NN
of/IN
the/DT
residues/NNS
in/IN
the/DT
holo/JJ
condition/NN
of/IN
both/DT
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
./.
====================
Based/VBN
on/IN
the/DT
in/FW
silico/JJ
approaches/NNS
employed/VBN
in/IN
this/DT
study/NN
,/,
the/DT
plausible/JJ
stable/JJ
homology/NN
models/NNS
of/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
of/IN
FASN/NN
protein/NN
are/VBP
suggested/VBN
,/,
which/WDT
are/VBP
also/RB
found/VBD
to/TO
be/VB
in/IN
substantial/JJ
agreement/NN
with/IN
the/DT
reported/VBN
crystal/JJ
structures/NNS
./.
====================
Further/RB
,/,
the/DT
favorable/JJ
outcomes/NNS
of/IN
substrate/NN
binding/NN
with/IN
the/DT
ER/NN
and/CC
KR/NN
domains/NNS
validate/VBP
the/DT
predicted/VBN
structures/NNS
and/CC
their/PRP$
potential/JJ
for/IN
screening/NN
anti-FASN/JJ
ligands/NNS
./.
====================
The/DT
insights/NNS
from/IN
this/DT
in/IN
silico/NN
study/NN
would/MD
be/VB
very/RB
helpful/JJ
in/IN
pharmacologic/JJ
lead/VBP
generation/NN
,/,
as/IN
FASN/NN
inhibition/NN
is/VBZ
favorably/RB
implicated/VBN
in/IN
the/DT
treatment/NN
of/IN
cancers/NNS
,/,
diabetes/VBZ
,/,
obesity/NN
,/,
and/CC
infections/NNS
./.
====================
(/(
A/NN
)/)
Overall/RB
topology/NN
of/IN
the/DT
enoyl/NN
reductase/NN
(/(
ER/NN
)/)
domain/NN
from/IN
N/NN
to/TO
C/NN
terminus/NN
./.
====================
(/(
B/NN
)/)
The/DT
3D/NN
structure/NN
of/IN
the/DT
ER/NN
domain/NN
;/:
helices/VBZ
are/VBP
shown/VBN
in/IN
red/JJ
,/,
beta/NN
sheets/NNS
in/IN
cyan/JJ
,/,
and/CC
turns/NNS
in/IN
green/CD
./.
====================
(/(
A/NN
)/)
Overall/RB
topology/NN
of/IN
the/DT
β-ketoacyl/NN
reductase/NN
(/(
KR/NN
)/)
domain/NN
from/IN
N/NN
to/TO
C/NN
terminus/NN
./.
====================
(/(
B/NN
)/)
The/DT
3D/NN
structure/NN
of/IN
the/DT
KR/NN
domain/NN
,/,
with/IN
helices/NNS
shown/VBN
in/IN
red/JJ
,/,
beta/NN
sheets/NNS
in/IN
cyan/JJ
,/,
and/CC
turns/NNS
in/IN
green/CD
./.
====================
Ramachandran/NN
plots/NNS
for/IN
the/DT
modeled/JJ
enoyl/NN
reductase/NN
domain/NN
(/(
A/NN
,/,
before/IN
refinement/JJ
;/:
B/NN
,/,
after/IN
refinement/JJ
)/)
./.
====================
Ramachandran/NN
plots/NNS
for/IN
the/DT
modeled/JJ
β-ketoacyl/NN
reductase/NN
domain/NN
(/(
A/NN
,/,
before/IN
refinement/JJ
;/:
B/NN
,/,
after/IN
refinement/JJ
)/)
./.
====================
Time-dependent/JJ
root/NN
mean/NN
square/VBP
deviation/NN
(/(
RMSD/NN
)/)
(/(
Å/NNP
)/)
and/CC
radius/NN
of/IN
gyration/NN
(/(
Å/NNP
)/)
for/IN
the/DT
enoyl/NN
reductase/NN
model/NN
during/IN
5-ns/NNS
molecular/JJ
dynamics/NNS
simulation/JJ
./.
====================
(/(
A/NN
)/)
The/DT
RMSD/NN
trajectories/VBZ
of/IN
the/DT
backbone/NN
atoms/NNS
for/IN
the/DT
apo-protein/NN
are/VBP
shown/VBN
in/IN
blue/JJ
and/CC
the/DT
holo-protein/NN
in/IN
red/JJ
./.
====================
(/(
B/NN
)/)
The/DT
radius/NN
of/IN
gyration/NN
trajectories/VBZ
for/IN
the/DT
apo-protein/NN
are/VBP
shown/VBN
in/IN
blue/JJ
and/CC
the/DT
holo-protein/NN
in/IN
red/JJ
./.
====================
Time-dependent/JJ
root/NN
mean/NN
square/VBP
deviation/NN
(/(
RMSD/NN
)/)
(/(
Å/NNP
)/)
and/CC
radius/NN
of/IN
gyration/NN
(/(
Å/NNP
)/)
for/IN
the/DT
β-ketoacyl/NN
reductase/NN
model/NN
during/IN
5/CD
ns/NNS
of/IN
molecular/JJ
dynamics/NNS
simulation/JJ
./.
====================
(/(
A/NN
)/)
The/DT
RMSD/NN
trajectories/VBZ
of/IN
the/DT
backbone/NN
atoms/NNS
of/IN
the/DT
apo-protein/NN
are/VBP
shown/VBN
in/IN
blue/JJ
and/CC
the/DT
holo-protein/NN
in/IN
red/JJ
./.
====================
(/(
B/NN
)/)
The/DT
radius/NN
of/IN
gyration/NN
trajectories/VBZ
for/IN
the/DT
apo-protein/NN
are/VBP
shown/VBN
in/IN
blue/JJ
and/CC
the/DT
holo-protein/NN
in/IN
red/JJ
./.
====================
Molecular/JJ
surface/NN
area/NN
of/IN
the/DT
enoyl/NN
reductase/NN
domain/NN
./.
====================
(/(
A/DT
)/)
Red/VBD
region/NN
shows/VBZ
the/DT
Rossmann/NN
fold/JJ
;/:
yellow/RB
region/NN
shows/VBZ
the/DT
nucleotide/NN
binding/NN
residues/NNS
,/,
and/CC
the/DT
blue/JJ
region/NN
shows/VBZ
the/DT
two/CD
donor/NN
residues/NNS
for/IN
protonation/NN
of/IN
the/DT
substrates/NNS
(/(
Lys1771/NN
and/CC
Asp1797/NN
)/)
./.
====================
(/(
B/NN
)/)
Depicts/NNS
the/DT
tunnel/NN
through/IN
which/WDT
the/DT
substrate/NN
moves/VBZ
into/IN
the/DT
next/JJ
domain/NN
./.
====================
Molecular/JJ
docking/NN
of/IN
enoyl/NN
reductase/NN
(/(
ER/NN
)/)
with/IN
its/PRP$
substrate/NN
./.
====================
(/(
A/NN
)/)
Substrate/NN
trans/JJ
butenoyl/NN
is/VBZ
docked/VBN
to/TO
the/DT
ER/NN
domain/NN
./.
====================
The/DT
substrate/NN
is/VBZ
shown/VBN
in/IN
ball/JJ
and/CC
stick/VBP
form/VBP
,/,
the/DT
hydrogen/NN
bond/NN
is/VBZ
a/DT
dotted/JJ
yellow/RB
line/NN
,/,
and/CC
weak/JJ
interactions/NNS
are/VBP
dotted/VBN
orange/NN
lines/NNS
./.
====================
(/(
B/NN
)/)
2D/NN
interaction/NN
map/VBP
of/IN
trans/JJ
butenoyl/NN
substrate/NN
with/IN
the/DT
ER/NN
domain/NN
./.
====================
Amino/DT
acids/NNS
are/VBP
mentioned/VBN
with/IN
3/CD
letter/NN
codes/VBZ
,/,
and/CC
arrow/NN
indicates/VBZ
hydrogen/NN
bonding/VBG
with/IN
Val1680/NN
./.
====================
Molecular/JJ
docking/NN
of/IN
β-ketoacyl/JJ
reductase/NN
(/(
KR/NN
)/)
with/IN
its/PRP$
substrate/NN
./.
====================
(/(
A/NN
)/)
Substrate/NN
β-ketobutyryl/NN
is/VBZ
docked/VBN
to/TO
the/DT
KR/NN
domain/NN
./.
====================
The/DT
substrate/NN
is/VBZ
shown/VBN
in/IN
ball/JJ
and/CC
stick/VBP
form/VBP
,/,
the/DT
hydrogen/NN
bond/NN
is/VBZ
a/DT
dotted/JJ
yellow/RB
line/NN
,/,
and/CC
weak/JJ
interactions/NNS
are/VBP
dotted/VBN
orange/NN
lines/NNS
./.
====================
(/(
B/NN
)/)
2D/NN
interaction/NN
map/VBP
of/IN
β-ketobutyryl/JJ
substrate/NN
to/TO
the/DT
KR/NN
domain/NN
./.
====================
Amino/DT
acids/NNS
are/VBP
mentioned/VBN
with/IN
3/CD
letter/NN
codes/VBZ
,/,
and/CC
arrow/NN
indicates/VBZ
hydrogen/NN
bonding/VBG
with/IN
Ser2021/NN
and/CC
Tyr2034/NN
./.
====================
Time-dependent/JJ
root/NN
mean/NN
square/NN
fluctuation/NN
(/(
RMSF/NN
)/)
plots/NNS
(/(
Angstrom/IN
)/)
./.
====================
(/(
A/NN
)/)
RMSF/NN
trajectory/JJ
plot/NN
of/IN
enoyl/NN
reductase/NN
domain/NN
showing/VBG
residue-wise/RB
fluctuation/NN
in/IN
apo/NN
(/(
blue/JJ
)/)
and/CC
holo/JJ
(/(
red/JJ
)/)
conditions/NNS
./.
====================
(/(
B/NN
)/)
RMSF/NN
trajectory/JJ
plot/NN
for/IN
β-ketoacyl/JJ
reductase/NN
(/(
KR/NN
)/)
domain/NN
showing/VBG
residue-wise/RB
fluctuation/NN
of/IN
KR/NN
domain/NN
in/IN
apo/NN
(/(
blue/JJ
)/)
and/CC
holo/JJ
(/(
red/JJ
)/)
conditions/NNS
./.
====================
